← All trials
NCT05706207
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 21, 2021
- Primary completion
- Sep 30, 2023
- Completion date
- Sep 30, 2023
- First posted
- Jan 31, 2023
- Last posted
- Jan 31, 2023
- Enrollment
- 36
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huabo Biopharm Co., Ltd.Lead sponsor
- Bengbu Medical CollegeCollaborator
- Bengbu Medical CollegeOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.